Evidence map›Paper›PMID 37750104›Full record

ArticleInternational journal of general medicine2023

14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with

Feifei Lu, Wentao Xu, Xiaoye Shi, Honglu Yu, Xingshun Qi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Feifei Lu *College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People's Republic of China.
Wentao Xu *Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People's Republic of China.
Xiaoye Shi *Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People's Republic of China.
Honglu Yu *Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People's Republic of China.
Xingshun QiCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People's Republic of China.ORCID 0000-0002-9448-6739
General Hospital of Shenyang Military Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Methods: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included. Results: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups. Conclusion: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with

Indexed as

bismuth quadruple therapyefficacyHelicobacter pyloripantoprazolevonoprazan

Identifiers

PMID37750104
PMCPMC10518141
OpenAlexW4386851004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.